PT  - JOURNAL ARTICLE
AU  - Matczak, Soraya
AU  - Levy, Corinne
AU  - Fortas, Camille
AU  - Cohen, Jérémie F.
AU  - Béchet, Stéphane
AU  - El Belghiti, Fatima Aït
AU  - Guillot, Sophie
AU  - Trombert-Paolantoni, Sabine
AU  - Jacomo, Véronique
AU  - Savitch, Yann
AU  - Paireau, Juliette
AU  - Brisse, Sylvain
AU  - Guiso, Nicole
AU  - Lévy-Bruhl, Daniel
AU  - Cohen, Robert
AU  - Toubiana, Julie
TI  - Association between the COVID-19 pandemic and pertussis in France using multiple nationwide data sources
AID  - 10.1101/2021.07.16.21260367
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.07.16.21260367
4099  - http://medrxiv.org/content/early/2021/07/20/2021.07.16.21260367.short
4100  - http://medrxiv.org/content/early/2021/07/20/2021.07.16.21260367.full
AB  - Background Interventions to mitigate coronavirus disease 19 (COVID-19) pandemic may impact other respiratory diseases such as pertussis. We aimed to study the course of pertussis in France over an 8-year period and its association with COVID-19 mitigation strategies, using multiple nationwide data sources.Methods We analyzed the number of French pertussis cases between 2013 and 2020, using the PCR test results from nationwide outpatient laboratories (Source 1) and the pediatric network of 41 hospitals (Source 2), and using the reports of an office-based pediatric national network (Source 3). We conducted a quasi-experimental interrupted time-series analysis, relying on negative binomial regression models. The models accounted for seasonality, long-term cycles, and secular trend, and included a binary variable for the first national lockdown (ordered on March 16, 2021).Results We identified 19,039 cases of pertussis from the three data sources during the study period. There was a significant decrease of pertussis cases following the implementation of mitigation measures, with adjusted incidence rate ratios of 0.102 (95% CI 0.040-0.256) and 0.216 (95% CI 0.071-0.656) for Source 1 and Source 2, respectively. The association was confirmed in Source 3 (median of 1 [IQR 0-2] vs. 0 [IQR 0-0] pertussis cases per month before and after lockdown, respectively, p=0.0048).Conclusion The drastic reduction of outpatient and hospitalized cases of pertussis strongly suggests an impact of COVID-19 mitigation measures and their consequences on pertussis epidemiology. Pertussis vaccination recommendations should be carefully followed, and disease monitoring should be continued to detect any resurgence after relaxation of mitigation measures.Funding There was no specific funding for the study.Competing Interest StatementCL, RC, SBe (for the French ambulatory surveillance of whooping cough for outpatient pediatric cases by ACTIV network) received funding from GlaxoSmithKline, MSD and Sanofi Pasteur. The other authors did not declare any conflict of interest.Clinical TrialThe data collections received approval by Institutional Review and Data protection Board (APHP, N: 2021 0608105701) for Source 1, and by the National Review Boards for Source 2 (CNIL N: 449199) and Source 3 (CNIL N: 1161396). Source 3 was registered at ClinicalTrials.gov (NCT04318431). All data processing and storage comply with the General Data Protection Regulation (GDPR) and ethical standards of the National Research Committee.Funding StatementThere was no specific funding for the study. ACTIV network was supported by GlaxoSmithKline, MSD, and Sanofi Pasteur.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data collections received approval by Institutional Review and Data protection Board (APHP, N: 2021 0608105701) for Source 1, and by the National Review Boards for Source 2 (CNIL N: 449199) and Source 3 (CNIL N: 1161396). Source 3 was registered at ClinicalTrials.gov (NCT04318431). All data processing and storage comply with the General Data Protection Regulation (GDPR) and ethical standards of the National Research Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes